Aug 13, 2020
Photocure appoints Genotests as exclusive partner for Hexvix in Chile
Jun 11, 2020
Photocure Enters into Final Agreement to Regain Worldwide Rights of Hexvix
May 16, 2020
AUA Abstracts Further Support Role for Cysview® in the Office Setting
May 11, 2020
Discovery Brings Bladder Cancer Patients Hope
Apr 27, 2020
Bladder Cancer: 10 Year Epidemiological Forecasts Across Seven Major Markets
Apr 27, 2020
Photocure Regains Worldwide Rights of Hexvix
Mar 05, 2020
Outlook on the $320M+ Bladder Cancer Drugs Market, 2020-2030
Jan 21, 2020
miR Scientific® Introduces New Paradigm for Precision Medicine at PMWC 2020
Jan 08, 2020
KDx Diagnostics announces FDA Breakthrough Device designation for URO17(TM), Innovative urine test for Bladder Cancer
Dec 20, 2019
Johnson & Johnson Acquires TARIS Biomedical with Focus on Transforming the Treatment of Bladder Cancer
Nov 11, 2019
Global Urothelial Carcinoma Market Insights, Epidemiology and Market Forecasts Report 2019-2028
Nov 05, 2019
Photocure: Cysview® Reimbursement Further Improved From January 2020
Oct 14, 2019
Global Bladder Cancer Therapeutics Industry
Sep 18, 2019
Researchers Shed Light on Bladder Cancer Population Not Receiving Curative Intent Therapy
Aug 13, 2019
Corinth MedTech Appoints Steven Duddy as New President and CEO
Jul 25, 2019
Acupath First Commercial Lab to Offer URO17(TM), Innovative New Bladder Cancer Biomarker
Jul 25, 2019
TARIS Announces Presentation of Clinical Data for TAR-302 for Overactive Bladder
Jul 10, 2019
TARIS Initiates Clinical Trial of TAR-200 in Combination with Opdivo® (nivolumab) for Patients with Muscle-Invasive Bladder Cancer
Jun 26, 2019
TARIS Announces Positive Results of Phase 1b Trial of TAR-200 in Muscle Invasive Bladder Cancer
Jun 24, 2019
Asieris Announces Completion of Enrollment for its US APL-1202 Phase Ib Clinical Trial